Pfizer’s Xeljanz is the fist-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States, and the first targeted oral therapy to launch for the moderate to severe UC population. Not only does Xeljanz provide a novel MOA in the UC market but, as an oral therapy, it also offers a notable delivery advantage compared with the biologics and will help fulfill an unmet need. However, the entrenchment of the TNF-ɑ inhibitors could pose a formidable barrier to uptake and the agent’s positioning in the treatment algorithm is yet to be determined. The Ulcerative Colitis Emerging Therapy series includes three waves that will track the awareness, trial, and usage of Xeljanz since its approval in late May 2018 for the treatment of UC. In addition, the series will examine physician-anticipated future trends in UC treatment and in particular Xeljanz’s uptake, as well as assess Pfizer’s promotional efforts.
Emerging Therapies: is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as the impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Geography: United States
Primary research: Survey of 75 U.S. gastroenterologists for each wave.